Metabolon Wins National Institute of Health (NIH) Award to Develop Test to Improve Polycystic Ovary Syndrome (PCOS) Diagnostic Accuracy
MORRISVILLE, N.C., Dec. 5, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced receipt of a National Institute of Health (NIH) award to improve the accuracy by which polycystic ovary syndrome (PCOS) can be diagnosed.
- PCOS is the most common cause of infertility worldwide, affecting an estimated 8-13% of women of childbearing age.
- Current diagnoses typically require pelvic exams and blood tests to obtain a hormone profile, glucose tolerance, and lipid measurements.
- This diagnostic algorithm likely misclassifies or outright misses a lot of cases," said Adam Kennedy, Associate Director of Research and Development at Metabolon.
- "Metabolon's work in this area will potentially bring PCOS diagnostic guidelines into the 21st century using highly advanced, cutting-edge metabolomics science."